These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 20069241)

  • 21. Severe liver dysfunction in a patient with multiple sclerosis: the guilty party is not always the disease-modifying therapy.
    Hotermans C; Belachew S; Moonen G; Delwaide J
    Mult Scler; 2009 Nov; 15(11):1378-9. PubMed ID: 19965562
    [No Abstract]   [Full Text] [Related]  

  • 22. Multiple sclerosis. Generic glatiramer acetate--a step toward cheaper MS drugs?
    Sørensen PS
    Nat Rev Neurol; 2016 Jan; 12(1):5-6. PubMed ID: 26635211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence for use of glatiramer acetate in multiple sclerosis.
    Comi G; Hartung HP; Martinelli Boneschi F
    Lancet Neurol; 2005 Feb; 4(2):75-6; discussion 76-7. PubMed ID: 15664539
    [No Abstract]   [Full Text] [Related]  

  • 24. Evidence for use of glatiramer acetate in multiple sclerosis.
    Caramanos Z; Arnold DL
    Lancet Neurol; 2005 Feb; 4(2):74-5; discussion 76-7. PubMed ID: 15664538
    [No Abstract]   [Full Text] [Related]  

  • 25. Confusion over UK beta-interferon "trials".
    Dean M
    Lancet; 2001 Nov; 358(9293):1619. PubMed ID: 11716901
    [No Abstract]   [Full Text] [Related]  

  • 26. Tolerability, adverse events and compliance to glatiramer acetate in 28 patients with multiple sclerosis using the drug continuously for at least six months.
    Fiore AP; Fragoso YD
    Arq Neuropsiquiatr; 2005 Sep; 63(3B):738-40. PubMed ID: 16258646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fatigue Improvement after Switching Multiple Sclerosis Treatment from Interferon-β to Glatiramer Acetate in Clinical Practice.
    Meca-Lallana J; Hernández L; Caminero AB; Girón JM; Cano-Orgaz A; Carcelén-Gadea M; Muñoz D; Durán-Ferreras E; Martín-Hernández J; Sánchez-de la Rosa R;
    Eur Neurol; 2016; 76(1-2):40-7. PubMed ID: 27376845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A place of first-line drugs in treatment of multiple sclerosis].
    Kasatkin DS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(12):145-151. PubMed ID: 28635741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glatiramer acetate treatment persistence - but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy: a prospective web-based patient-centred study (CAIR study).
    Jongen PJ; Lemmens WA; Hoogervorst EL; Donders R
    Health Qual Life Outcomes; 2017 Mar; 15(1):50. PubMed ID: 28292329
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk-benefit assessment of glatiramer acetate in multiple sclerosis.
    Ziemssen T; Neuhaus O; Hohlfeld R
    Drug Saf; 2001; 24(13):979-90. PubMed ID: 11735654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".
    Filippi M; Rovaris M; Rocca MA; Sormani MP; Wolinsky JS; Comi G;
    Neurology; 2001 Aug; 57(4):731-3. PubMed ID: 11524494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple sclerosis: therapeutic update.
    Tselis AC; Lisak RP
    Arch Neurol; 1999 Mar; 56(3):277-80. PubMed ID: 10190816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glatiramer acetate: successful desensitization for treatment of multiple sclerosis.
    Bains SN; Hsieh FH; Rensel MR; Radojicic C; Katz HT; Inamdar SR; Lang DM
    Ann Allergy Asthma Immunol; 2010 Apr; 104(4):321-5. PubMed ID: 20408342
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis.
    Comi G; Cohen JA; Arnold DL; Wynn D; Filippi M;
    Ann Neurol; 2011 Jan; 69(1):75-82. PubMed ID: 21280077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis.
    Sormani MP; Rovaris M; Valsasina P; Wolinsky JS; Comi G; Filippi M
    Neurology; 2004 Apr; 62(8):1432-4. PubMed ID: 15111692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Glatiramer for relapsing-remitting multiple sclerosis].
    Hennemann A
    Med Monatsschr Pharm; 2002 Apr; 25(4):141-2. PubMed ID: 12017128
    [No Abstract]   [Full Text] [Related]  

  • 37. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.
    Clegg A; Bryant J; Milne R
    Health Technol Assess; 2000; 4(9):i-iv, 1-101. PubMed ID: 10944743
    [No Abstract]   [Full Text] [Related]  

  • 38. Inhibition of naive Th1 CD4+ T cells by glatiramer acetate in multiple sclerosis.
    Kantengwa S; Weber MS; Juillard C; Benkhoucha M; Fellay B; Zamvil SS; Gougeon ML; Chofflon M; Lalive PH
    J Neuroimmunol; 2007 Apr; 185(1-2):123-9. PubMed ID: 17306890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concomitant therapy for multiple sclerosis.
    Stuart WH; Vermersch P
    Neurology; 2004 Dec; 63(11 Suppl 5):S28-34. PubMed ID: 15596733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Localized lipoatrophy after glatiramer acetate injection in patients with remitting-relapsing multiple sclerosis.
    Drago F; Brusati C; Mancardi G; Murialdo A; Rebora A
    Arch Dermatol; 1999 Oct; 135(10):1277-8. PubMed ID: 10522686
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.